Literature DB >> 6453169

Antibiotic levels in infected and sterile subcutaneous abscesses in mice.

K A Joiner, B R Lowe, J L Dzink, J G Bartlett.   

Abstract

The pharmacokinetic properties of 10 antimicrobial agents were examined in sterile and infected encapsulated subcutaneous abscesses in mice. The inoculum for sterile abscesses was autoclaved cecal contents; that for infected abscesses was autoclaved cecal contents combined with Bacteroides fragilis. The antimicrobial agents examined were rosaramicin, clindamycin, chloramphenicol, metronidazole, and six beta-lactam antibiotics. All antimicrobial agents entered abscesses, produced peak levels of biological activity that were somewhat delayed in comparison to serum levels, and were present in negligible levels 8 hr after administration. The highest concentration in abscesses was achieved with rosaramicin and clindamycin, with peak levels of 43%--63% of the peak serum level. Peak levels of other antimicrobial agents in sterile abscesses were 13%--27% of the peak serum level. Levels of biologically active during were significantly lower in infected abscesses than in sterile abscesses for antimicrobial agents that are inactivated by B. fragilis beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6453169     DOI: 10.1093/infdis/143.3.487

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Antibiotic-induced modification of Bacteroides fragilis and its susceptibility to phagocytosis by human polymorphonuclear leukocytes.

Authors:  C G Gemmell; P K Peterson; D Schmeling; J Mathews; P G Quie
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

2.  Rifampin blood and tissue levels in patients undergoing cardiac valve surgery.

Authors:  G L Archer; B C Armstrong; B J Kline
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

Review 3.  Cephalosporins in surgery. Prophylaxis and therapy.

Authors:  D W McEniry; S L Gorbach
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams; L Morrison
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.

Authors:  Khalid H Ibrahim; Brent W Gunderson; Elizabeth D Hermsen; Laurie B Hovde; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Interactions with fibronectin attenuate the virulence of Streptococcus pyogenes.

Authors:  Patrik Nyberg; Takao Sakai; Kyu Hong Cho; Michael G Caparon; Reinhard Fässler; Lars Björck
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

7.  Cefoxitin inactivation by Bacteroides fragilis.

Authors:  G J Cuchural; F P Tally; N V Jacobus; P K Marsh; J W Mayhew
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

8.  Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency.

Authors:  Lee G Klinkenberg; Lesley A Sutherland; William R Bishai; Petros C Karakousis
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

Review 9.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

10.  In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics.

Authors:  David F Bruhn; Michael S Scherman; Jiuyu Liu; Dimitri Scherbakov; Bernd Meibohm; Erik C Böttger; Anne J Lenaerts; Richard E Lee
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.